In a long-term open-label extension study of adults with Sjogren disease, efgartimod therapy maintained its safety profile. Efgartimod therapy is well-tolerated in adults with Sjögren disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results